Unconventional therapies for cancer: 4. Hydrazine sulfate

CMAJ. Canadian Medical Association Journal

Volumn 158, Issue 10, 1998, Pages 1327-1330

  Kaegi, Elizabeth ^a   Schneider, Marilyn ^b  

^a Societe canadienne du cancer   (Canada)

^b Can Breast Cancer Res Initiative   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; BARBITURIC ACID DERIVATIVE; HYDRAZINE; HYDRAZINE SULFATE; TRANQUILIZER; TYRAMINE;

CANCER; CANCER CHEMOTHERAPY; DROWSINESS; DRUG CONTRAINDICATION; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG SAFETY; EXCITATION; FOOD DRUG INTERACTION; GLUCONEOGENESIS; HUMAN; NAUSEA; ORAL DRUG ADMINISTRATION; PERIPHERAL NEUROPATHY; PRURITUS; SHORT SURVEY; SIDE EFFECT; VERTIGO;

EID: 0032546567     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (58)

1. Warburg O. On the origin of cancer cells. Science 1956;123:309-14.
2. Macbeth RAL, Bekesi JG. Oxygen consumption and anaerobic glycolysis of human malignant and normal tissue. Cancer Res 1962;22:244-8.
3. Gold J. Metabolic profiles in human solid tumors: I. A new technic for the utilization of human solid tumors in cancer research and its application to the anaerobic glycolysis of isologous benign and malignant colon tissues. Cancer Res 1966;26:695-705.
4. Gold J. Proposed treatment of cancer by inhibition of gluconeogenesis. Oncology 1968;22:185-207.
5. Ray PD, Foster DO, Lardy HA. Paths of carbon in gluconeogenesis and lipogenesis: IV. Inhibition by L-tryptophan of hepatic gluconeogenesis at the level of phosphoenolpyruvate formation. J Biol Chem 1966;241(17):3904-8.
6. Gold J. Inhibition of Walker 256 intramuscular carcinoma in rats by administration of L-tryptophan. Oncology 1970;24(4):291-303.
7. Ray PD, Hanson RL, Lardy HA. Inhibition by hydrazine of gluconeogenesis in the rat. J Biol Chem 1970;245(4):690-6.
8. Gold J. Inhibition of gluconeogenesis at the phosphoenolpyruvate carboxykinase and pyruvate carboxylase reactions, as a means of cancer chemotherapy. Oncology 1974;29:74-89.
9. Gold J. Inhibition of Walker 256 intramuscular carcinoma in rats by administration of L-tryptophan and hydrazine sulfate [abstract 116]. Proc Am Assoc Cancer Res 1970;11:30.
10. Gold J. Inhibition of Walker 256 intramuscular carcinoma in rats by administration of hydrazine sulfate. Oncology 1971;25:66-71.
11. Gold J. Use of hydrazine sulfate in terminal and preterminal cancer patients: results of investigational new drug (IND) study in 84 evaluable patients. Oncology 1975;32:1-10.
12. Gold J. Anabolic profiles in late-stage cancer patients responsive to hydrazine sulfate. Nutr Cancer 1981;3(1):13-9.
13. Ontario Breast Cancer Information Exchange Project. A guide to unconventional cancer therapies. Aurora (ON): R&R Bookbar; 1994. p. 278-80.
14. Chlebowski RT, Bulcavage L, Grosvenor M, Oktay E, Block JB, Chlebowski JS, et al. Hydrazine sulfate influence in nutritional status and survival in non-small-cell lung cancer. J Clin Oncol 1990;8(1):9-15.
15. Gold J. Enhancement by hydrazine sulfate of antitumor effectiveness of cytoxan, mitomycin C, methotrexate and bleomycin, in Walker 256 carcinosarcoma in rats. Oncology 1975;31:44-53.
16. Chlebowski RT, Heber D, Richardson B, Block JB. Influence of hydrazine sulfate on abnormal carbohydrate metabolism in cancer patients with weight loss. J Cancer Res 1984;44:857-61.
17. Tweedie DJ, Erikson JM, Prough RA. Metabolism of hydrazine anti-cancer agents. Pharmacol Ther 1987;34:111-27.
18. Noda A, Sendo T, Ohno K, Noda H, Goto S. Metabolism and cytotoxicity of hydrazine in isolated rat hepatocytes. Chem Pharma Bull (Tokyo) 1987;35 (6):2538-44.
19. Gold J. Incompatibility of hydrazine sulfate and pentobarbital in the treatment of tumor hearing animals [abstract 999]. Proc Am Assoc Cancer Res 1977; 18:250.
20. Suzuki H, Tominaga T, Mizuno H, et al. Ethanol and hydrazine sulfate induced chronic hepatic injury in rats: the curative effect of administration of glucogenic amino acids. Alcohol Alcohol Suppl 1993;1A:111-7.
21. Zimmerman HJ, Ishak KG. The hepatic injury of monoamine oxidase inhibitors. J Clin Psychapharmacol 1987;7(4):211-3.
22. Berkow R, editor. The Merck manual of diagnosis and therapy. 16th ed. Toronto: WB Saunders Publishers; 1992.
23. Toth B. Hydrazine, methylhydrazine and methylhydrazine sulfate carcinogenesis in Swiss mice: failure of ammonium hydroxide to interfere in the development of tumors. Int J Cancer 1972;9:109-18.
24. Menon MM, Bhide SV. Perinatal carcinogenicity ot isoniazid (INH) in Swiss mice. J Cancer Res Clin Oncol 1983;105:258-61.
25. Baló J. Role of hydrazine in carcinogenesis. Adv Cancer Res 1979;30:151-64.
26. Bosan WS, Shrank RC, MacEwan JD, Gaworski CL, Newberne PM. Methylation of DNA guanine during the course of induction of liver cancer in hamsters by hydrazine or dimethylnitrosamine. Carcinogenesis 1987;8:439-44.
27. Toth B. Teratogenic hydrazines: a review. In Vivo 1993;7(1):101-10.
28. Silverstein R, Christoffersen CA, Morrison DC. Modulation of endotoxin lethality in mice by hydrazine sulfate. Infect Immun 1989;57(7):2072-8.
29. Chlebowski RT, Heber D. Metaholic abnormalities in cancer patients: carbohydrate metabolism. Surg Clin North Am 1986;66(5):957-68.
30. Filov VA, Burova TM. [Gluconeogenesis during therapy of experimental tumors with hydrazine sulfate] (Russian). Biull Eksp Biol Med 1984;97(1):73-4.
31. Grubbs B, Rogers W, Cameron I. Total parenteral nutrition and inhibition of gluconcogenesis on tumor-host responses. Ocology 1979;36:216-23.
32. Gold J. Potentiation by clofibrate of in vivo tumor inhibition by hydrazine sulfate and cytotoxic agents, in Walker 256 intramuscular carcinoma. Cancer Biochem Biophys 1978;3(1):41-5.
33. Nelson JAS, Falk RK. The efficacy of phloridzin and phloretin on tumor cell growth. Anticancer Res 1993;13:2287-92.
34. Ottery FD. Supportive nutrition to prevent cachexia and improve quality of life. Semin Oncol 1995;22(2 Suppl 3):98-111.
35. Chlebowski RT, Dietrich M, Tsunokai R, Block JB. Hydrazine sulfate: clinical pharmacokinetics and influence on in vitro growth of human glioblastoma cell lines [abstract 1002]. Proc Am Assoc Cancer Res 1985;26:254.
36. Filov VA, Gershanovich ML, Ivin BA, Danova LA, Gurchin FA, Naryshkin AG, et al. [Therapy of primary brain rumors with Schydrin] (Russian). Vopr Onkol 1994;40(7-12):332-6.
37. Gold J. Inhibition by hydrazine sulfate and various hydrazides, of in vivo growth of Walker 256 intramuscular carcinoma, B-16 melanoma, Murphy-Sturm lymphosarcoma and L-1210 solid leukemia. Oncology 1973;27:69-80.
38. Ochoa M Jr, Wittes RE, Krakoff IH. Trial of hydrazine sulfate (NSC150014) in patients with cancer. Cancer Chemother Rep 1975;59(6):1151-4.
39. 14C-lysine metabolism in lung cancer patients. Lancet 1987;2:241-3.
40. Bruera E. Current management of anorexia and cachexia in patients with advanced cancer. Oncology 1992;49(Suppl 2):35-42.
41. Parnes HL, Aisner J. Protein calorie malnutrition and cancer therapy. Drug Saf 1996;7(6):404-16.
42. Pisters PWT, Pearlstone DB. Protein and amino acid metabolism in cancer cachexia: investigative techniques and therapeutic interventions. Crit Rev Clin Lab Sci 1993;30(3):223-72.
43. Strum SB, Bierman HR, Thompson R. Hydrazine sulfate in patients with neoplasia [abstract 1090]. Proc Am Assoc Cancer Res 1975;16:243.
44. Lerner HJ, Regelson W. Clinical trial of hydrazine sulfate in solid tumors. Cancer Treat Rep 1976;60(7):959-60.
45. Kosty MP, Fleishman SB, Herndon JE, Coughlin K, Kornblith AB, Scalzo A, et al. Cisplatin, vinblastine, and hydrazine sulfate in advanced, non-small-cell lung cancer: a randomized placebo-controlled, double blind phase III study of the cancer and leukemia group B. J Clin Oncol 1994;12(6):1113-20.
46. Loprinzi CL, Kuross SA, O'Fallon JR, Gesme DH, Gerstner JB, Respond RM, et al. Randomized placebo-controlled evaluation of hydrazine sulfate in patients with advanced colorectal cancer. J Clin Oncol 1994;12(6):1121-5.
47. Loprinzi CL, Goldherg RM, Su JQ, Mailliard JA, Kuross SA, Maksymiuk AW, et al. Placebo-controlled trial of hydrazine sulfate in patients with newly diagnosed non-small-cell lung cancer. J Clin Oncol 1994;12(6):1126-9.
48. Gershanovich ML, Danova LA, Kondratyev VB, Malyugina LL, Stukov AN, Seitz JF, et al. Clinical data on the antitumor activity of hydrazine sulfate. Cancer Treat Rep 1976;60(7):933-5.
49. Gershanovich ML, Danova LA, Ivin BA, Filov VA. Results of clinical study of antitumor action of hydrazine sulfate. Nutr Cancer 1981;3(1):7-12.
50. Gold J. Hydrazine sulfate: a current perspective [review]. Nutr Cancer 1987;9(2-3):59-66.
51. Filov VA, Danova LA, Gershanovich ML, Ivin BA, Dementyeva NP, Beyvis PV, et al. Results of clinical evaluation of hydrazine sulfate. Vopr Onkol 1990 ;36(6):721-6.
52. Gold J. Hydrazine sulfate in the treatment of cancer. Cancer Treat Rep 1976;60(7):964-5.
53. Piantadosi S. Hazards of small clinical trials. J Clin Oncol 1990;8(1):1-3.
54. Gold J. Hydrazine sulfate in nonsmall-cell lung cancer. J Clin Oncol 1990;8:1117-8.
55. Herbert V. Three stakes in hydrazine sulfate's heart, but questionable cancer remedies, like vampires, always rise again. J Clin Oncol 1994;12(6):1107-8.
56. Kosty MP, Herndon JE, Green MR, McIntyre OR. Placebo-controlled randomized study of hydrazine sulfate in lung cancer. J Clin Oncol 1995;13(6): 1529-30.
57. Kamen J. The cancer empire strikes back. Penthouse 1994;Nov:104-5.
58. Steinhardt B, director, Health Services Quality and Public Issues, US General Accounting Office, Washington. Letter to Leonard Weiss, PhD, Minority Staff Director, Senate Committee on Governmental Affairs; 1998 Jan 8. [Letter in public domain; on file with the Canadian Breast Cancer Research Initiative.]